The global induced pluripotent stem cells production market size was estimated to be USD 1.50 billion in 2023 and is expected to reach at USD 4.17 billion by 2034 with a CAGR of 9.74% during the forecast period 2024-2034. Rising incidence of cancer, growing investments for stem cell-based research, increasing research & development activities on pluripotent stem cells, surge in technological advancements, rising investments for the integration of automation in induced pluripotent stem cells (iPSCs) production, & gaining insights into functionality through omics-based data, growing focus on the development of a strong therapy product pipeline, and increasing introduction of advanced platforms for induced pluripotent stem cells production are some of the key factors boosting the market growth.
Increasing introduction of advanced platforms for induced pluripotent stem cells production is predicted to boost the market growth during the forecast period. Induced pluripotent stem cells (iPSCs) are a category of pluripotent stem cells created through the induction of specific genes. iPSCs are produced by introducing a defined set of genes, often those associated with pluripotency, into fully developed somatic cells. The emergence of iPSCs has opened up new opportunities in clinical research, regenerative medicine, and disease modeling, leading to the introduction of numerous new products. For instance, in July 2022, Curi Bio has unveiled the Mantarray platform, designed for the analysis of contractile activity in 3D cardiac and skeletal engineered muscle tissue (EMT), which is relevant to human applications.
By product, consumables & kits was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the continuous research & development efforts in the field of induced pluripotent stem cells (iPSCs), rising adoption of kits & media during toxicology testing, growing demand for various induced pluripotent stem cells (iPSCs) kits, including reprogramming kits, differentiation kits, & generation kits, and increasing investment by leading market players. For instance, in November 2022, REPROCELL Inc. has made the decision to invest in Histocell S.L. with the aim of enhancing its clinical Induced Pluripotent Stem Cell (Ipsc) Services. Histocell is a Contract Development and Manufacturing Organization (CDMO) situated in Bilbao, Spain, and it operates an approved Advanced Therapy Medical Product (ATMP) manufacturing facility that provides Good Manufacturing Practice (GMP)-grade manufacturing services for cell therapy products. Additionally, Histocell is involved in the development of its clinical pipelines centered around adipose-derived mesenchymal stem cells (AMSC) for various target indications. Additionally, automated platforms is predicted to grow at fastest CAGR during the forecast period owing to the rising demand for stem cell products, expansion of clinical-phase induced pluripotent stem cell (iPSC) therapies, and surge in implementation of rigorous regulatory quality control measures.
By process, manual iPSC production process was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the rising demand by companies with proficiency in tissue procurement, gene introduction, RNA reprogramming, & cell culture and growing collaborations within market players. For instance, in October 2023, REPROCELL Inc. has disclosed that it has reached an agreement to provide Gameto Inc., a biotechnology company primarily led by women and dedicated to revolutionizing women's healthcare, with a non-exclusive license to utilize REPROCELL's StemRNA Clinical Seed iPSCs. These clinical-grade induced pluripotent stem cells (iPSCs) will play a role in the development and launch of Gameto's Fertilo Program, which aims to enhance in vitro fertilization (IVF) and the egg freezing process. Additionally, automated iPSC production process is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for stem cell-based therapies requires scaling up and rising need to consistently produce large quantities of induced pluripotent stem cells (iPSCs) with minimal variations.
By workflow, cell culture was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to rising investments by major market players and growing number of clinical trial procedures. For instance, in April 2022, Editas Medicine, Inc. has revealed in vitro and in vivo preclinical data showcasing the improved tumor-killing capabilities of engineered induced pluripotent stem cell (iPSC)-derived natural killer or iNK cell therapies. These advancements were achieved through the utilization of Editas Medicine's proprietary gene editing platform. Additionally, cell characterization/analysis is predicted to grow at fastest CAGR during the forecast period owing to the increasing use of assays based on cells in drug discovery due to their consistency in producing tissue-specific results, growing prevalence of chronic diseases such as cancer, rising use of cell-based assays for detection & treatment.
By application, drug development & discovery was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to increasing prevalence of chronic diseases, and rising collaborations within market players. For instance, in February 2022, Edigene, Inc. and Neukio Biotherapeutics have joined forces for collaborative development and research with the aim of advancing next-generation immune cell therapies by harnessing induced pluripotent stem cells (iPSC) and natural killer cells (NK cells). Additionally, regenerative medicine segment is predicted to grow at fastest CAGR during the forecast period owing to the extensive range of applications and strong product pipelines offered by various companies and surge in drug discovery for innovative therapeutics.
By end-user, biotechnology & pharmaceutical companies was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the availability & utilization of a diverse range of kits, consumables, instruments, & iPSCs-related products and continuous development of new products through intensive research and development endeavors. For instance, in October 2022, Fate Therapeutics, Inc. has disclosed that they will be presenting clinical and preclinical data related to their induced pluripotent stem cell (iPSC) product platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in Boston, MA, and will also be available virtually from November 8 to 12, 2022. Additionally, research & academic institutes is predicted to grow at fastest CAGR during the forecast period owing to the wide applications of iPSCs & utilized in research & clinical studies, rising utilization of iPSCs in regenerative studies, and expanding research environment dedicated to assessing the safety and effectiveness of induced pluripotent stem cell (iPSC)-based therapies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in incidences of chronic diseases, rising healthcare infrastructure, increasing funding from private & government organizations, growing number of clinical trials for iPSCs, and surge in collaborations within market players. For instance, in May 2022, A strategic partnership between Evotec and Sernova aims to create a beta replacement therapy based on induced pluripotent stem cells (iPSCs) for the treatment of both type 1 and type 2 diabetes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the intensified, cost-effective research in stem cell-based approaches, supported by the growth of economies & improvements in healthcare systems, rising awareness regarding the potential of personalized treatments, the existence of numerous start-up ventures, academic institutions, & collaborative initiatives involving international companies, and increasing new product/service launches. For instance, in June 2023, REPROCELL has introduced a new commercial service known as Pharmacology-AI. This launch follows the successful conclusion of one of the initial EXCELERATE projects, conducted by the Hartree National Centre for Digital Innovation (HNCDI) in partnership with the Science and Technology Facilities Council (STFC) Hartree Centre and IBM.
Increasing introduction of advanced platforms for induced pluripotent stem cells production is predicted to boost the market growth during the forecast period. Induced pluripotent stem cells (iPSCs) are a category of pluripotent stem cells created through the induction of specific genes. iPSCs are produced by introducing a defined set of genes, often those associated with pluripotency, into fully developed somatic cells. The emergence of iPSCs has opened up new opportunities in clinical research, regenerative medicine, and disease modeling, leading to the introduction of numerous new products. For instance, in July 2022, Curi Bio has unveiled the Mantarray platform, designed for the analysis of contractile activity in 3D cardiac and skeletal engineered muscle tissue (EMT), which is relevant to human applications.
By product, consumables & kits was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the continuous research & development efforts in the field of induced pluripotent stem cells (iPSCs), rising adoption of kits & media during toxicology testing, growing demand for various induced pluripotent stem cells (iPSCs) kits, including reprogramming kits, differentiation kits, & generation kits, and increasing investment by leading market players. For instance, in November 2022, REPROCELL Inc. has made the decision to invest in Histocell S.L. with the aim of enhancing its clinical Induced Pluripotent Stem Cell (Ipsc) Services. Histocell is a Contract Development and Manufacturing Organization (CDMO) situated in Bilbao, Spain, and it operates an approved Advanced Therapy Medical Product (ATMP) manufacturing facility that provides Good Manufacturing Practice (GMP)-grade manufacturing services for cell therapy products. Additionally, Histocell is involved in the development of its clinical pipelines centered around adipose-derived mesenchymal stem cells (AMSC) for various target indications. Additionally, automated platforms is predicted to grow at fastest CAGR during the forecast period owing to the rising demand for stem cell products, expansion of clinical-phase induced pluripotent stem cell (iPSC) therapies, and surge in implementation of rigorous regulatory quality control measures.
By process, manual iPSC production process was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the rising demand by companies with proficiency in tissue procurement, gene introduction, RNA reprogramming, & cell culture and growing collaborations within market players. For instance, in October 2023, REPROCELL Inc. has disclosed that it has reached an agreement to provide Gameto Inc., a biotechnology company primarily led by women and dedicated to revolutionizing women's healthcare, with a non-exclusive license to utilize REPROCELL's StemRNA Clinical Seed iPSCs. These clinical-grade induced pluripotent stem cells (iPSCs) will play a role in the development and launch of Gameto's Fertilo Program, which aims to enhance in vitro fertilization (IVF) and the egg freezing process. Additionally, automated iPSC production process is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for stem cell-based therapies requires scaling up and rising need to consistently produce large quantities of induced pluripotent stem cells (iPSCs) with minimal variations.
By workflow, cell culture was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to rising investments by major market players and growing number of clinical trial procedures. For instance, in April 2022, Editas Medicine, Inc. has revealed in vitro and in vivo preclinical data showcasing the improved tumor-killing capabilities of engineered induced pluripotent stem cell (iPSC)-derived natural killer or iNK cell therapies. These advancements were achieved through the utilization of Editas Medicine's proprietary gene editing platform. Additionally, cell characterization/analysis is predicted to grow at fastest CAGR during the forecast period owing to the increasing use of assays based on cells in drug discovery due to their consistency in producing tissue-specific results, growing prevalence of chronic diseases such as cancer, rising use of cell-based assays for detection & treatment.
By application, drug development & discovery was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to increasing prevalence of chronic diseases, and rising collaborations within market players. For instance, in February 2022, Edigene, Inc. and Neukio Biotherapeutics have joined forces for collaborative development and research with the aim of advancing next-generation immune cell therapies by harnessing induced pluripotent stem cells (iPSC) and natural killer cells (NK cells). Additionally, regenerative medicine segment is predicted to grow at fastest CAGR during the forecast period owing to the extensive range of applications and strong product pipelines offered by various companies and surge in drug discovery for innovative therapeutics.
By end-user, biotechnology & pharmaceutical companies was the highest revenue-grossing segment in the global induced pluripotent stem cells production market in 2023 owing to the availability & utilization of a diverse range of kits, consumables, instruments, & iPSCs-related products and continuous development of new products through intensive research and development endeavors. For instance, in October 2022, Fate Therapeutics, Inc. has disclosed that they will be presenting clinical and preclinical data related to their induced pluripotent stem cell (iPSC) product platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in Boston, MA, and will also be available virtually from November 8 to 12, 2022. Additionally, research & academic institutes is predicted to grow at fastest CAGR during the forecast period owing to the wide applications of iPSCs & utilized in research & clinical studies, rising utilization of iPSCs in regenerative studies, and expanding research environment dedicated to assessing the safety and effectiveness of induced pluripotent stem cell (iPSC)-based therapies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in incidences of chronic diseases, rising healthcare infrastructure, increasing funding from private & government organizations, growing number of clinical trials for iPSCs, and surge in collaborations within market players. For instance, in May 2022, A strategic partnership between Evotec and Sernova aims to create a beta replacement therapy based on induced pluripotent stem cells (iPSCs) for the treatment of both type 1 and type 2 diabetes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the intensified, cost-effective research in stem cell-based approaches, supported by the growth of economies & improvements in healthcare systems, rising awareness regarding the potential of personalized treatments, the existence of numerous start-up ventures, academic institutions, & collaborative initiatives involving international companies, and increasing new product/service launches. For instance, in June 2023, REPROCELL has introduced a new commercial service known as Pharmacology-AI. This launch follows the successful conclusion of one of the initial EXCELERATE projects, conducted by the Hartree National Centre for Digital Innovation (HNCDI) in partnership with the Science and Technology Facilities Council (STFC) Hartree Centre and IBM.
Segmentation: Induced Pluripotent Stem Cells Production Market Report 2023 - 2034
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments/Devices
- Automated Platforms Consumables & Kits
- Services
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by Process 2023 - 2034 (Revenue USD Bn)
- Automated IPSC Production Process
- Manual IPSC Production Process
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by Workflow 2023 - 2034 (Revenue USD Bn)
- Cell Characterization/Analysis
- Cell Culture
- Reprogramming
- Engineering
- Others
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Regenerative Medicine
- Toxicology Studies
- Drug Development & Discovery
- Others
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research & Academic Institutes
- Hospitals & Clinics
- Biotechnology & Pharmaceutical Companies
Induced Pluripotent Stem Cells Production Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Induced Pluripotent Stem Cells Production Market: Product Estimates & Trend Analysis
8. Induced Pluripotent Stem Cells Production Market: Process Estimates & Trend Analysis
9. Induced Pluripotent Stem Cells Production Market: Workflow Estimates & Trend Analysis
10. Induced Pluripotent Stem Cells Production Market: Application Estimates & Trend Analysis
11. Induced Pluripotent Stem Cells Production Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Induced Pluripotent Stem Cells Production Market
14. Europe Global Induced Pluripotent Stem Cells Production Market
15. Asia Pacific Global Induced Pluripotent Stem Cells Production Market
16. Latin America Global Induced Pluripotent Stem Cells Production Market
17. MEA Global Induced Pluripotent Stem Cells Production Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- StemCellsFactory III
- Axol Bioscience Ltd.
- Merck KGaA
- REPROCELL Inc.
- Lonza
- Hitachi Ltd.
- Applied StemCells Inc.
- Evotec
- Fate Therapeutics
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 4.17 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
